Drug intelligence / Profile preview

tuvonralimab

Development stage: Phase 4
Lead developer: Qilu Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Tuvonralimab is one of two unique monoclonal antibodies that constitute QL1706, a bifunctional PD-1/CTLA-4 antibody developed by Qilu Pharmaceutical Co., Ltd. QL1706 is designed as a synergistic dual immunotherapy for advanced solid tumors. It has shown promising anti-tumor activity in non-small cell lung cancer, nasopharyngeal carcinoma, and cervical cancer, and received conditional approval for cervical cancer in China in September 2024.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on tuvonralimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tuvonralimab.

Explore the full profile